April 2019 Vol 5 No 2
By Lisa Lurie
Lisa Lurie went from “bald, breastless, and bewildered” to all-glammed-up as a cancer survivor and founder of Cancer Be Glammed, a nonprofit organization that empowers women to recover with dignity and positive self-esteem. Last fall, Lisa was a finalist for CONQUER’s Hero of Hope Patient Award, and although she didn’t win, this experience was a milestone in her cancer story. Read More ›
By Kelsey Moroz
Obesity is associated with about 40% of cancers in the United States. This link is strongest in several types of cancer, including kidney, gastric, pancreatic, endometrial, and esophageal cancer. Significant weight reduction may help to reduce the risk for cancer. Read More ›
For artist Celeste Baldwin, whose work is featured on the cover of the April issue of CONQUER, flowers represent life. She painted this art after completing treatment for breast cancer. Read More ›
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer. Read More ›
By Sal Gregory
With an infant son and a difficult-to-treat breast cancer, Sal Gregory decided she had to gather strength through her faith and positive attitude. Read More ›
Nutrition plays a very important role during and after cancer treatment. Cancer dietitian Julie Lanford provides practical tips on what may be the best choices for you during treatment, and how to maintain a healthy diet when treatment is over. Read More ›
Martin Miralda was fresh out of college when a short visit to the United States helped to save his life after he was diagnosed with leukemia. Despite his lacking health insurance as a non-resident, he received superior medical care through “Charity Care,” a service that covers necessary hospitalization for uninsured people in the country and is available in several states. Read More ›
This new chemotherapy-free combination of Imbruvica, a targeted therapy, plus Gazyva, a CD20-directed cytolytic antibody, was recently approved by the FDA as first-line treatment of adults aged 65 or older who are newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read More ›